Analysts Set Sabra Healthcare REIT Inc. (NASDAQ:SBRA) Target Price at $22.35
Sabra Healthcare REIT Inc. (NASDAQ:SBRA) has been given an average recommendation of “Hold” by the seventeen ratings firms that are presently covering the firm. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $22.86.
SBRA has been the topic of several analyst reports. Zacks Investment Research lowered shares of Sabra Healthcare REIT from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Sabra Healthcare REIT in a research report on Friday, September 9th. Citigroup Inc. lifted their target price on shares of Sabra Healthcare REIT from $22.00 to $24.00 and gave the company a “neutral” rating in a research report on Wednesday, August 17th. BTIG Research initiated coverage on shares of Sabra Healthcare REIT in a research report on Thursday, August 25th. They issued a “neutral” rating on the stock. Finally, JMP Securities reiterated a “hold” rating on shares of Sabra Healthcare REIT in a research report on Friday, September 9th.
Shares of Sabra Healthcare REIT (NASDAQ:SBRA) opened at 23.77 on Monday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of 28.40 and a beta of 1.05. Sabra Healthcare REIT has a 52-week low of $14.92 and a 52-week high of $26.40. The company has a 50-day moving average of $24.70 and a 200-day moving average of $22.29.
Sabra Healthcare REIT (NASDAQ:SBRA) last released its quarterly earnings results on Monday, August 1st. The company reported $0.61 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.03. The company had revenue of $74.20 million for the quarter, compared to analyst estimates of $56.04 million. Sabra Healthcare REIT had a net margin of 24.63% and a return on equity of 6.27%. The firm’s revenue was up 31.1% on a year-over-year basis. During the same quarter last year, the business earned $0.53 earnings per share. Equities research analysts anticipate that Sabra Healthcare REIT will post $2.28 EPS for the current year.
Several large investors have recently added to or reduced their stakes in SBRA. Nuveen Asset Management LLC increased its stake in Sabra Healthcare REIT by 1,393.6% in the second quarter. Nuveen Asset Management LLC now owns 1,021,636 shares of the company’s stock worth $21,081,000 after buying an additional 953,235 shares during the period. Norges Bank bought a new stake in Sabra Healthcare REIT during the fourth quarter worth about $12,022,000. Vanguard Group Inc. increased its stake in Sabra Healthcare REIT by 3.0% in the second quarter. Vanguard Group Inc. now owns 10,251,855 shares of the company’s stock worth $211,547,000 after buying an additional 302,868 shares during the period. JPMorgan Chase & Co. increased its stake in Sabra Healthcare REIT by 74.2% in the second quarter. JPMorgan Chase & Co. now owns 664,139 shares of the company’s stock worth $13,705,000 after buying an additional 282,887 shares during the period. Finally, Systematic Financial Management LP bought a new stake in Sabra Healthcare REIT during the second quarter worth about $4,343,000. 92.14% of the stock is currently owned by institutional investors and hedge funds.
About Sabra Healthcare REIT
Sabra Health Care REIT, Inc is a real estate investment trust. The Company owns and invests in real estate serving the healthcare industry. The Company’s segment is investments in healthcare-related real estate properties. Its primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.
Receive News & Stock Ratings for Sabra Healthcare REIT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT Inc. and related stocks with our FREE daily email newsletter.